How wide is the gap between
the dose that works and the dose that harms?
An efficacy study looks at one point — does it work at this dose. A toxicity study looks at the whole curve — where does it start to harm.
Over these 20 lessons you design the dose groups, justify how high the top dose goes, read the clinical chemistry and the histopathology, and set a NOAEL by hand — then see why that call is a judgement rather than a statistic. It ends with the system that makes every record of it believable: GLP.
How you'll learn
Efficacy ends at "does it work"; toxicity has to answer from where. That is why there are four dose groups — and why the top group is supposed to show toxicity.
p < 0.05 does not mean toxicity. Is there a dose-response, is there a morphological correlate, is it a background finding — you ask each of these yourself.
One ALT value settles nothing. A target organ is called only when clinical chemistry, organ weight and histopathology all point the same way.
GLP does not demand good science — it demands that every record can be reconstructed. You see exactly where that line falls.